Results 61 to 70 of about 2,453,026 (292)
Journal of Research in Medical Sciences, 2015 Background: Factor V G1691A (FV Leiden), FII GA20210, and methylenetetrahydrofolate reductase (MTHFR) C677T mutations are the most common genetic risk factors for thromboembolism in the Western countries.
Mohammad Saadatnia +10 more
doaj +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background Type 1 plasminogen deficiency (PLGD‐1) is an ultra‐rare autosomal recessive disorder caused by variants in the PLG gene and affects approximately 1.6 individuals per million. The condition is characterized by decreased plasminogen levels and impaired function, resulting in fibrin‐rich lesions on mucous membranes throughout the body.
Charles Nakar +7 more
wiley +1 more source
MTHFR C677T mutation, factor II G20210A mutation and factor V Leiden as risks factor for youth retinal vein occlusion. [PDF]
, 2003 Objective: To determine whether methylene tetrahydrofolate reductase (MTHFR) C677T mutation, factor II G20210A mutation and factor V Leiden are risk factors for retinal vein occlusion (RVO) in patients under fifty years of age.
CONTI L +7 more
core
Factor V Leiden Mutation and Stroke
Pediatric Neurology Briefs, 2001 The association of the factor V Leiden mutation and cerebrovascular disorder (CVD) in children is reviewed and the clinical features of 8 children with cerebral palsy (CP) and the Leiden mutation are described from the National Institute of Neurological ...
J Gordon Millichap
doaj +1 more source
Factor V Leiden and Inflammation [PDF]
Thrombosis, 2012 Factor V Leiden, is a variant of human factor V (FV), also known as proaccelerin, which leads to a hypercoagulable state. Along these years, factor V Leiden (FVL) has been studied from the pathophysiologic point of view, and research has been focused on finding clinical approaches for the management of the FVL associated to a trombophilic state.
Silvia Perez-Pujol +2 more
openaire +2 more sources
Pediatric Blood &Cancer, EarlyView.ABSTRACT Introduction The use of herbal medical preparation (HMP) is rising among pediatric oncology patients, often to manage treatment‐related symptoms. Their effectiveness remains uncertain, and the risk of herb–drug interactions is underestimated.
Orianne Mahot +6 more
wiley +1 more source
Development of acquired factor V inhibitor after treatment with ceftazidime: a case report and review of the literature [PDF]
, 2015 Qing-ya Cui,1 Hong-shi Shen,1 Tian-qin Wu,1 Hai-fei Chen,1 Zi-qiang Yu,2 Zhao-yue Wang2 1Department of Hematology, PLA 100th Hospital, 2Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, People’s ...
Wu TQ +5 more
core
Novel Factor V C2-Domain Mutation (R2074H) in Two Families with Factor V Deficiency and Bleeding [PDF]
, 2002 SummaryThe molecular basis of Factor V deficiency has been defined in few patients only. We report a homozygous nucleotide change (G6395A) in two Tunisian probands with Factor V deficiency and bleeding episodes.
I. Schrijver +4 more
core +1 more source
Is Factor V Leiden a Risk Factor for Fetal Loss?
Acta Medica, 1999 A successful pregnancy is dependent on the development of adequate placental circulation. The abnormalities of placental vasculature may result in a number of gestational pathologies, including fetal loss.
Petr Dulíček +5 more
doaj +1 more source
Immunochemical Studies of Factor V [PDF]
European Journal of Biochemistry, 1975 Native bovine factor V exhibits a molecular weight of 300000 as determined by gel filtration of untreated plasma. Highly purified factor V exhibits multiple molecular weight forms which range from small active fragments to aggregates of several million which are generated during the purification on cellulose phosphate.
A C, Greenquist +3 more
openaire +2 more sources